Developer docs
API playgroundTry for free, no card

Search company profiles

Rare Therapeutics

Full company profile

uuid00rzu3g

Namestring
Rare Therapeutics
Legal namestring
Rare Therapeutics, Inc.
Websiteurl
raretx.us
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Rare Therapeutics, Inc. (RareTx) is a clinical-stage gene therapy company that launched on October 7, 2025 as an affiliate of GEMMABio, headquartered at 125 S. 31st St., Philadelphia, PA. The company is built on Dr. Jim Wilson's 40-year career pioneering the development and delivery of gene therapies for rare diseases, and focuses exclusively on ultra-rare lysosomal storage diseases — specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD) — targeting patient populations with prevalence under 1:100,000 where no approved treatments currently exist. Its technology foundation is a next-generation gene delivery and manufacturing platform developed through decades of research investment, intended to enable platform-based development across multiple ultra-orphan indications rather than single-product economics.

Raretx has not yet generated revenue and remains pre-commercial, with 1–10 employees at formation and no disclosed external funding rounds or institutional investors. Its intended go-to-market is structurally unconventional for gene therapy: rather than premium pricing through standard commercial channels, the company plans to distribute its therapies through an international coalition of public-private partnerships and regional centers of excellence designed to ensure affordable worldwide access. The strategic premise is that ultra-rare diseases are too small to justify traditional investment models, and that novel funding architectures combined with platform technology can produce a sustainable pipeline of treatments. Near-term strategic signals include broad coverage in tier-one biotech media (Fierce Biotech, Endpoints News, BioBuzz) and selection as a Philadelphia Business Journal 'Startup to Watch' for 2026, but financial scale, pipeline progression timelines, and partnership economics remain undisclosed.

Short descriptiontext

Rare Therapeutics (RareTx) is a clinical-stage gene therapy company, spun out of GEMMABio in October 2025, developing treatments for ultra-rare lysosomal storage diseases (GM1, Krabbe, MLD) for delivery through an international coalition of public-private partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy development, ultra-rare disease therapeutics, lysosomal storage diseases, clinical-stage biotechnology, rare disease treatments
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Gene therapy product sales
TypeOne Time License
Description

Revenue derived from developing and commercializing gene therapy treatments for ultra-rare lysosomal storage diseases including GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy. The company aims to enhance quality and affordability of gene therapy products through international public-private partnerships.

raretx.us
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Rare Therapeutics (RareTx) is a clinical-stage biotechnology company developing gene therapies for ultra-rare lysosomal storage diseases, specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company leverages next-generation gene delivery and manufacturing technologies built on Dr. Jim Wilson's 40-year pioneering research, and distributes treatments through an international coalition of public-private partnerships to enable affordable global access.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Only 5% of rare diseases currently have available treatments, creating significant unmet medical need
+2 more records
Product overview1 text field

RareTx is a clinical-stage therapeutics company with a single unified gene therapy product pipeline targeting three lysosomal storage diseases: GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company operates as an affiliate of GEMMABio and is building on Dr. Jim Wilson's pioneering work in gene therapy. Treatments are delivered through an international coalition of public-private partnerships to enable affordable access to ultra-orphan disease patients globally.

Product and service1 record
1Gene Therapy Pipeline (GM1, Krabbe disease, MLD)
CategoryGene Therapy
Description

Clinical-stage gene therapy portfolio targeting ultra-rare lysosomal storage diseases (GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy), developed using next-generation gene delivery and manufacturing technologies and delivered through an international coalition of public-private partnerships to ensure affordable global access for patients with these conditions.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOthersAnnounced on2025-10-07
Description

RareTx is an affiliate of GEMMABio, which launched the company on October 7, 2025. GEMMABio provides strategic support and backing to Rare Therapeutics, enabling the company to enhance quality and affordability of gene therapy products while leading to greater access and a sustainable pipeline of treatments for ultra-rare diseases.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

REGENXBIO develops AAV gene therapy platforms and treatments for rare diseases, including partnerships across multiple rare disease programs; comparable as a gene delivery technology provider adjacent to RareTx's AAV modality.

TypeDirect peer
Description

Passage Bio is a clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases, directly comparable to RareTx in modality (AAV gene therapy), disease area (rare neurological), and development stage.

TypeDirect peer
Description

Prevail Therapeutics develops AAV-based gene therapies for neurodegenerative diseases, including approaches for lysosomal storage and CNS disorders that overlap directly with RareTx's GM1, Krabbe, and MLD targets.

TypeBroad incumbent
Description

Spark Therapeutics pioneered approved AAV gene therapies (e.g., Luxturna) and operates as Roche's gene therapy unit, representing a broader incumbent in rare disease AAV gene therapy development and commercialization.

TypeDirect peer
Description

Solid Biosciences is a clinical-stage gene therapy company focused on rare neuromuscular and CNS diseases, comparable to RareTx in clinical-stage AAV gene therapy development for underserved rare populations.

TypeDirect peer
Description

Lexeo Therapeutics is a clinical-stage gene therapy company targeting rare diseases including CNS and cardiac indications, overlapping with RareTx's rare disease AAV gene therapy positioning and platform approach.

7bluebird bio
TypeBroad incumbent
Description

bluebird bio is a gene therapy company developing treatments for severe genetic diseases including rare neurological and metabolic conditions, comparable to RareTx's focus on ultra-rare genetic disorders via advanced therapy modalities.

TypeBroad incumbent
Description

BioMarin is a global rare disease biopharmaceutical company with approved enzyme replacement and gene therapies for conditions including certain lysosomal storage diseases, operating as a broad incumbent addressing similar patient populations.

TypeDirect peer
Description

Taysha Gene Therapies is a clinical-stage gene therapy company developing AAV-based therapies for ultra-rare CNS disorders, with a pipeline model closely mirroring RareTx's ultra-orphan CNS-focused strategy.

TypeBroad incumbent
Description

Ultragenyx is a commercial-stage rare disease biopharmaceutical company with multiple approved therapies and gene therapy programs, including for lysosomal storage diseases - a broader incumbent competing across the same rare disease category as RareTx.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rare Therapeutics

Gene Therapyraretx.us

Rare Therapeutics (RareTx) is a clinical-stage gene therapy company, spun out of GEMMABio in October 2025, developing treatments for ultra-rare lysosomal storage diseases (GM1, Krabbe, MLD) for delivery through an international coalition of public-private partnerships.

What Rare Therapeutics does

Rare Therapeutics, Inc. (RareTx) is a clinical-stage gene therapy company that launched on October 7, 2025 as an affiliate of GEMMABio, headquartered at 125 S. 31st St., Philadelphia, PA. The company is built on Dr. Jim Wilson's 40-year career pioneering the development and delivery of gene therapies for rare diseases, and focuses exclusively on ultra-rare lysosomal storage diseases — specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD) — targeting patient populations with prevalence under 1:100,000 where no approved treatments currently exist. Its technology foundation is a next-generation gene delivery and manufacturing platform developed through decades of research investment, intended to enable platform-based development across multiple ultra-orphan indications rather than single-product economics.

Raretx has not yet generated revenue and remains pre-commercial, with 1–10 employees at formation and no disclosed external funding rounds or institutional investors. Its intended go-to-market is structurally unconventional for gene therapy: rather than premium pricing through standard commercial channels, the company plans to distribute its therapies through an international coalition of public-private partnerships and regional centers of excellence designed to ensure affordable worldwide access. The strategic premise is that ultra-rare diseases are too small to justify traditional investment models, and that novel funding architectures combined with platform technology can produce a sustainable pipeline of treatments. Near-term strategic signals include broad coverage in tier-one biotech media (Fierce Biotech, Endpoints News, BioBuzz) and selection as a Philadelphia Business Journal 'Startup to Watch' for 2026, but financial scale, pipeline progression timelines, and partnership economics remain undisclosed.

Rare Therapeutics firmographics

Firmographics
Name
Rare Therapeutics
Legal name
Rare Therapeutics, Inc.
Website
https://raretx.us
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Rare Therapeutics (RareTx) is a clinical-stage gene therapy company, spun out of GEMMABio in October 2025, developing treatments for ultra-rare lysosomal storage diseases (GM1, Krabbe, MLD) for delivery through an international coalition of public-private partnerships.
Ownership category
akta.pro rank

Rare Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Gene therapy development
  • Ultra-rare disease therapeutics
  • Lysosomal storage diseases
  • Clinical-stage biotechnology
  • Rare disease treatments

Where Rare Therapeutics is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rare Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gene therapy product sales: Revenue derived from developing and commercializing gene therapy treatments for ultra-rare lysosomal storage diseases including GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy. The company aims to enhance quality and affordability of gene therapy products through international public-private partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Rare Therapeutics product offering

Product offering

Core offering

Rare Therapeutics (RareTx) is a clinical-stage biotechnology company developing gene therapies for ultra-rare lysosomal storage diseases, specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company leverages next-generation gene delivery and manufacturing technologies built on Dr. Jim Wilson's 40-year pioneering research, and distributes treatments through an international coalition of public-private partnerships to enable affordable global access.

Product overview

RareTx is a clinical-stage therapeutics company with a single unified gene therapy product pipeline targeting three lysosomal storage diseases: GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company operates as an affiliate of GEMMABio and is building on Dr. Jim Wilson's pioneering work in gene therapy. Treatments are delivered through an international coalition of public-private partnerships to enable affordable access to ultra-orphan disease patients globally.

Differentiator

Problem solved

Functional benefit

Products and services

  • Gene Therapy Pipeline (GM1, Krabbe disease, MLD) Clinical-stage gene therapy portfolio targeting ultra-rare lysosomal storage diseases (GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy), developed using next-generation gene delivery and manufacturing technologies and delivered through an international coalition of public-private partnerships to ensure affordable global access for patients with these conditions.

Quantifiable outcome

  • Only 5% of rare diseases currently have available treatments, creating significant unmet medical need
  • +2 more outcomes

Companies that use Rare Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Rare Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Rare Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GEMMABiocoreOthers · 7 October 2025RareTx is an affiliate of GEMMABio, which launched the company on October 7, 2025. GEMMABio provides strategic support and backing to Rare Therapeutics, enabling the company to enhance quality and affordability of gene therapy products while leading to greater access and a sustainable pipeline of treatments for ultra-rare diseases.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Rare Therapeutics competitors and assessment

Company assessment

Emerging players

  • REGENXBIO: REGENXBIO develops AAV gene therapy platforms and treatments for rare diseases, including partnerships across multiple rare disease programs; comparable as a gene delivery technology provider adjacent to RareTx's AAV modality.

Direct peers

  • Passage Bio: Passage Bio is a clinical-stage AAV gene therapy company focused on rare monogenic CNS diseases, directly comparable to RareTx in modality (AAV gene therapy), disease area (rare neurological), and development stage.
  • Prevail Therapeutics (Eli Lilly): Prevail Therapeutics develops AAV-based gene therapies for neurodegenerative diseases, including approaches for lysosomal storage and CNS disorders that overlap directly with RareTx's GM1, Krabbe, and MLD targets.
  • Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company focused on rare neuromuscular and CNS diseases, comparable to RareTx in clinical-stage AAV gene therapy development for underserved rare populations.
  • Lexeo Therapeutics: Lexeo Therapeutics is a clinical-stage gene therapy company targeting rare diseases including CNS and cardiac indications, overlapping with RareTx's rare disease AAV gene therapy positioning and platform approach.
  • Taysha Gene Therapies: Taysha Gene Therapies is a clinical-stage gene therapy company developing AAV-based therapies for ultra-rare CNS disorders, with a pipeline model closely mirroring RareTx's ultra-orphan CNS-focused strategy.

Broad incumbents

  • Spark Therapeutics (Roche): Spark Therapeutics pioneered approved AAV gene therapies (e.g., Luxturna) and operates as Roche's gene therapy unit, representing a broader incumbent in rare disease AAV gene therapy development and commercialization.
  • bluebird bio: bluebird bio is a gene therapy company developing treatments for severe genetic diseases including rare neurological and metabolic conditions, comparable to RareTx's focus on ultra-rare genetic disorders via advanced therapy modalities.
  • BioMarin Pharmaceutical: BioMarin is a global rare disease biopharmaceutical company with approved enzyme replacement and gene therapies for conditions including certain lysosomal storage diseases, operating as a broad incumbent addressing similar patient populations.
  • Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease biopharmaceutical company with multiple approved therapies and gene therapy programs, including for lysosomal storage diseases - a broader incumbent competing across the same rare disease category as RareTx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Rare Therapeutics social profiles

Digital presence

Rare Therapeutics compliance and trust

Trust signal

Compliance1 record

Rare Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rare Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Rare Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rare Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rare Therapeutics

What does Rare Therapeutics do?

Rare Therapeutics (RareTx) is a clinical-stage biotechnology company developing gene therapies for ultra-rare lysosomal storage diseases, specifically GM1 gangliosidosis, Krabbe disease, and metachromatic leukodystrophy (MLD). The company leverages next-generation gene delivery and manufacturing technologies built on Dr. Jim Wilson's 40-year pioneering research, and distributes treatments through an international coalition of public-private partnerships to enable affordable global access.

Is Rare Therapeutics a public or private company?

Rare Therapeutics is a private company. It is classified as corporate owned and is currently operating.

When was Rare Therapeutics founded?

Rare Therapeutics was founded in 2025. It employs 1 to 10 people.

Where is Rare Therapeutics based?

Rare Therapeutics is headquartered in Philadelphia, United States, in the North America region.

How does Rare Therapeutics make money?

One revenue line is on record: gene therapy product sales.

Who are Rare Therapeutics's main competitors?

REGENXBIO is listed as an emerging player. Direct peers are Passage Bio, Prevail Therapeutics (Eli Lilly), Solid Biosciences, Lexeo Therapeutics and Taysha Gene Therapies. Broad incumbents are Spark Therapeutics (Roche), bluebird bio, BioMarin Pharmaceutical and Ultragenyx Pharmaceutical.

Does Rare Therapeutics have an API?

No public API is recorded for Rare Therapeutics.

What industry is Rare Therapeutics in?

Rare Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals